LobbyingKedrion Biopharma lobbying by quarter
Kedrion Biopharma's latest lobbying report covers Q2 2026, at under $5,000. The four quarters Q3 2025–Q2 2026 total $450K. Its first report covers Q2 2025; the issues it reports most are Trade (Domestic & Foreign).
Kedrion Biopharma
- Latest quarter
- $0
- Q2 2026 · 1 reports
- Last 12 months
- $450K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q2 2026 against the quarter before
- First report
- Q2 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2025 | $170K | 1 |
| Q3 2025 | $170K | 1 |
| Q4 2025 | $140K | 1 |
| Q1 2026 | $140K | 1 |
| Q2 2026 | $0 | 1 |
Policy issues the reports name
- Trade5 reports
A report that names several issues counts once for each.
Who was lobbied
- U.S. Trade Representative (USTR)5 reports
- Commerce, Dept of (DOC)4 reports
- HOUSE OF REPRESENTATIVES4 reports
- SENATE3 reports
- Centers For Medicare and Medicaid Services (CMS)2 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Prime Policy Group | $620K | 5 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Prime Policy Group | Under $5,000 |
| 04/08for Q1 | Prime Policy Group | $140K |
| 01/15for Q4 2025 | Prime Policy Group | $140K |
| 25/10/20for Q3 2025 | Prime Policy Group | $170K |
| 25/07/22for Q2 2025 | Prime Policy Group | $170K |
| 25/07/21for Q2 2025 | Prime Policy Group | Under $5,000 |